Contract for the supply of human papillomavrius vaccine

The provision of a vaccine to prevent highgrade cervical intraepithelial neoplasia (CIN grades 2 and 3) and cervical cancer causally related to Human Papillomavirus types 16 and 18, to be used in the national immunisation programme, and deliveries will be required over a period of 2 years, with an option to extend for up to an additional 24 months.